Dark

SRPT
Sarepta Therapeutics,, Inc. Common Stock
stock NASDAQ

At Close

Dec 5, 2025 3:59:58 PM EST

22.26USD-2.432%(-0.56)2,659,310

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 5, 2025 9:28:30 AM EST

22.81USD-0.044%(-0.01)9,947

After-hours

Dec 5, 2025 4:58:30 PM EST

22.25USD-0.067%(-0.01)53,417

OverviewOptionsHistoricalExchangesShortsNews

Jan 31, 2022

06:15PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jan 18, 2022

01:02PM EST Analyst Ratings For Sarepta Therapeutics Benzinga

10:41AM EST Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $92 Benzinga

Jan 13, 2022

12:08PM EST Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate Benzinga

11:47AM EST The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact Benzinga

11:43AM EST Lysogene Announced Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights Benzinga

Jan 10, 2022

10:56AM EST Sarepta Shares To Resume Trade 11:10 a.m. EST Benzinga

10:51AM EST Sarepta Therapeutics Reports Its SRP-9001 Showed Statistically Significant Improvements vs Pre-Specified Matched External Control In Part 2 Of Study Benzinga

10:50AM EST -- Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001 compared to pre-specified matched external control cohort ( p value=0.0009) -- Results continue to reinforce the tolerability profile of SRP-9001 with no new safety signals identified GlobeNewswire Inc

10:40AM EST UPDATE: Sarepta Slide Show Presentation For JP Morgan Healthcare Conference Shows Safety Profile For SRP-9001-102 In Part 2 Trial Was Consistent With Result Seen In Part 1 Benzinga

10:40AM EST Sarepta Power Point Slides For JP Morgan Healthcare Conference Presentation Show Conclusions From Co.'s SRP-9001-102: Patients Treated In Part 2 Study Improved 2 Points vs Predefined External Control Group Benzinga

10:38AM EST UPDATE: Sarepta Therapeutics Has Released Slides For JP Morgan Conference Benzinga

10:37AM EST Sarepta Therapeutics Now Presenting At JP Morgan Conference Benzinga

10:27AM EST Sarepta Shares Halted Ahead Of 10:30 a.m. EST Presentation At JP Morgan Healthcare Conference Monday Benzinga

10:24AM EST Sarepta Therapeutics Shares Halted On Code News Pending Benzinga

Jan 6, 2022

08:33AM EST -- Presentation on Monday, Jan. 10, 2022, to include topline results from Part 2 of Study SRP-9001-102 GlobeNewswire Inc

Jan 5, 2022

07:17AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

06:06AM EST Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $150 Benzinga

Dec 31, 2021

08:45PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Dec 9, 2021

09:52PM EST Expert Ratings For Sarepta Therapeutics Benzinga

09:50PM EST Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 Benzinga

09:45PM EST Oppenheimer Upgrades Sarepta Therapeutics to Outperform, Announces $125 Price Target Benzinga

Nov 30, 2021

06:17PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Nov 18, 2021

05:16AM EST Sarepta Therapeutics CEO Douglas Ingram Reported Purchase of 25,026 Shares @ Avg Price of $79.94/Share in Form 4 Filing on Wednesday Benzinga

Nov 17, 2021

08:40AM EST Sarepta Therapeutics Appoints Stephen Mayo To Board RTTNews

08:31AM EST -- Gilmore ONeill, M.B., M.M.Sc.,will depart the Company and serve in a consulting capacity through March 31, 2022 GlobeNewswire Inc

08:30AM EST -- A renowned expert in protein engineering, Dr. Mayo brings extensive scientific expertise and strong business acumen to the Companys board GlobeNewswire Inc

Nov 5, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 Benzinga

09:36AM EDT JP Morgan Upgrades Sarepta Therapeutics to Overweight, Raises Price Target to $130 Benzinga

09:27AM EDT Analyst Ratings For Sarepta Therapeutics Benzinga

Nov 4, 2021

08:52AM EDT RBC Capital Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $145 Benzinga

06:03AM EDT Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $157 Benzinga

Nov 3, 2021

05:29PM EDT Sarepta Therapeutics Q3 Loss/share $0.60 Vs. Loss $2.50 Year Ago RTTNews

04:45PM EDT Sarepta Therapeutics Q3 EPS $(0.19) May Not Compare To $(1.89) Estimate, Sales $189.40M Beat $173.42M Estimate Benzinga

04:01PM EDT -- Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior year -- In light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million GlobeNewswire Inc

09:19AM EDT The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 29, 2021

06:15PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Oct 27, 2021

08:30AM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2021 financial results and to provide a corporate update. GlobeNewswire Inc

Oct 15, 2021

12:16PM EDT Expert Ratings For Sarepta Therapeutics Benzinga

07:48AM EDT Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $95 Benzinga

Oct 13, 2021

09:15PM EDT Sarepta Therapeutics Announces Pricing of $500 Million Public GlobeNewswire Inc

01:38PM EDT The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal Benzinga

06:21AM EDT A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes Benzinga

Oct 12, 2021

04:05PM EDT UPDATE: Sarepta Reports Had ~$1.6B In Cash, Cash Equivalents, Investments As Of Sept. 30, 2021 Benzinga

04:04PM EDT Sarepta Sees Q3 Net Product Sales ~$166.9M Benzinga

04:04PM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021. GlobeNewswire Inc

04:02PM EDT Sarepta Therapeutics Announces Proposed $500M Public Offering of Common Stock Benzinga

04:01PM EDT Sarepta Therapeutics Announces Proposed $500,000,000 Public GlobeNewswire Inc

12:24PM EDT What 5 Analyst Ratings Have To Say About Sarepta Therapeutics Benzinga

09:26AM EDT Credit Suisse Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $100 Benzinga

08:08AM EDT BTIG Maintains Buy on Sarepta Therapeutics, Raises Price Target to $125 Benzinga

Oct 11, 2021

12:18PM EDT Sarepta Therapeutics Option Alert: Jan 21 $100 Calls at the Ask: 2490 @ $12.0 vs 1843 OI; Earnings 11/4 After Close [est] Ref=$94.36 Benzinga

09:16AM EDT Sarepta Therapeutics Says Co's SRP-9001 Shows Sustained Functional Improvements In Multiple Studies Of Patients With Duchenne Benzinga

09:13AM EDT Sarepta Therapeutics SRP-9001 Shows Sustained GlobeNewswire Inc

Oct 4, 2021

04:30PM EDT -- Center dedicated to research and development activities to advance Sareptas industry-leading, multi-platform pipeline -- The Center encompasses 85,000 square feet of space, tripling Sareptas footprint in Ohio GlobeNewswire Inc

07:27AM EDT Sarepta Therapeutics Begins Pivotal Study Of SRP-9001 For The Treatment Of Duchenne Muscular Dystrophy RTTNews

07:11AM EDT Sarepta Therapeutics Initiates its EMBARK Study of SRP-9001 to Treat Duchenne Muscular Dystrophy Benzinga

07:00AM EDT - Sarepta to host SRP-9001 Micro-dystrophin R&D Day at 8:30 a.m. Eastern Time on Monday, Oct. 11, 2021 GlobeNewswire Inc

Sep 30, 2021

07:07PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 27, 2021

08:35AM EDT Sarepta Therapeutics To Initiate Part B Of MOMENTUM Study Of SRP-5051 In Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping Benzinga

08:30AM EDT - Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful- Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will Be Eligible to Enroll in Part B of MOMENTUM GlobeNewswire Inc

Sep 19, 2021

09:46AM EDT The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions and Conference Presentations In The Spotlight Benzinga

Sep 15, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021 Benzinga

07:32AM EDT Guggenheim Upgrades Sarepta Therapeutics to Buy Benzinga

Sep 14, 2021

08:30AM EDT Sarepta Therapeutics to Showcase Data from its Gene Therapy and GlobeNewswire Inc

Sep 7, 2021

04:30PM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: GlobeNewswire Inc

08:30AM EDT Sarepta Therapeutics Announces Recipients of Route 79, The GlobeNewswire Inc

Sep 4, 2021

04:04PM EDT The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More Benzinga

Aug 31, 2021

05:57PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Aug 16, 2021

09:11AM EDT Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $90 Benzinga

Aug 13, 2021

10:17AM EDT CORRECTION: Support.Com Ticker Is 'SPRT' Benzinga

Aug 5, 2021

10:07AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021 Benzinga

09:55AM EDT Sarepta Therapeutics Shares Surge RTTNews

08:14AM EDT Credit Suisse Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $75 Benzinga

05:34AM EDT JP Morgan Upgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $87 Benzinga

Aug 4, 2021

04:23PM EDT Sarepta Therapeutics Q2 EPS $(1.52) Misses $(1.29) Estimate, Sales $141.80M Miss $162.64M Estimate Benzinga

04:05PM EDT Sarepta Therapeutics Announces Second Quarter 2021 Financial GlobeNewswire Inc

09:28AM EDT Sarepta Therapeutics Earlier Announced Execution Of Licensing Agreement For Gene Therapy Program From Nationwide Children's Hospital To Treat Limb-Girdle Muscular Dystrophy Type 2A; Financial Details Not Disclosed Benzinga

08:30AM EDT Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Aug 3, 2021

10:54AM EDT Sarepta Therapeutics's Earnings: A Preview Benzinga

Jul 30, 2021

05:43PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 28, 2021

08:30AM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2021 financial results and to provide a corporate update. GlobeNewswire Inc

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 22, 2021

10:18AM EDT Sarepta Therapeutics Shares Quiet, Co. Files U.S. Patent Application Titled, 'EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY' Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jun 30, 2021

06:41PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

07:00AM EDT BTIG Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target of $110 Benzinga

Jun 4, 2021

10:48AM EDT Sarepta Therapeutics Option Alert: Jan 21 $175 Calls Sweep (29) near the Ask: 200 @ $1.399 vs 33 OI; Ref=$73.01 Benzinga

Jun 3, 2021

May 28, 2021

06:55PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

May 18, 2021

02:02PM EDT Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study Benzinga

10:24AM EDT Shares of Sarepta Therapeutics, Inc. (SRPT) are currently gaining about 10% after the company announced positive results from a study of investigational treatment for a rare muscle disorder. RTTNews

09:29AM EDT Sarepta Therapeutics Inc. (SRPT) said that its investigational gene therapy for the treatment of duchenne muscular dystrophy, SRP-9001, demonstrated robust expression and consistent safety profile using the company's commercial process material. RTTNews

09:10AM EDT Sarepta Reports Positive 12-wk Expression, Safety Results From First 11 Participants In SRP-9001-103 RTTNews

08:51AM EDT Sarepta Therapeutics Reports Its Duchenne Muscular Dystrophy Treatment Showed Expression, Consistent Profile Using Co.'s Commercial Process Material Benzinga

08:51AM EDT Sarepta Therapeutics Investigational Gene GlobeNewswire Inc

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 17, 2021

04:22PM EDT Sarepta Therapeutics To Share Expression And Safety Results From Study 103 Evaluating SRP-9001, Its Investigational Gene Therapy For The Treatment Of Duchenne Muscular Dystrophy May 18 Benzinga

04:05PM EDT Sarepta Therapeutics to Share Expression and Safety Results from GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 5, 2021

04:44PM EDT Sarepta Therapeutics Q1 EPS $(2.10) Misses $(1.78) Estimate, Sales $146.93M Beat $143.33M Estimate Benzinga

04:05PM EDT -- Net product sales for the first quarter 2021 of $124.9 million, a 24% increase over the same quarter of prior year GlobeNewswire Inc

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 3, 2021

01:22PM EDT Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients Benzinga

08:52AM EDT Sarepta Therapeutics Reports Clinical Results From Phase 2 MOMENTUM Study Of SRP-5051 In Patients With Duchenne Muscular Dystrophy Amenable To Skipping Exon 51; Delivered Mean Exon Skipping Of 10.79% And Mean Dystrophin Expression Of 6.55% Benzinga

08:50AM EDT Sarepta Therapeutics Reports Positive Clinical Results from Phase GlobeNewswire Inc

08:03AM EDT Urges Shareholders to Vote the WHITE Proxy Card FOR ALL Four of MIMEDXs Director Nominees Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner GlobeNewswire Inc

Apr 30, 2021

06:45PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

04:05PM EDT Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of GlobeNewswire Inc

Apr 28, 2021

08:30AM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update. GlobeNewswire Inc

Apr 26, 2021

04:05PM EDT Sarepta Recommends Stockholders Reject the Below-Market GlobeNewswire Inc

Apr 19, 2021

11:16AM EDT Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $93 Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 13, 2021

08:16AM EDT The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug Benzinga

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 26, 2021

07:28AM EDT The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs Benzinga

Mar 25, 2021

07:58AM EDT The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut Benzinga

Mar 23, 2021

08:30AM EDT -- Application website is now open for the 2021 Scholarship Program -- GlobeNewswire Inc

Mar 19, 2021

07:46AM EDT The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs Benzinga

Mar 18, 2021

04:34PM EDT Sarepta Therapeutics Reports Its SRP-9003 For Treatment Of Limb-Girdle Muscular Dystrophy Type-2E Shows Sustained Expression, Functional Improvements 2 Years After Administration Benzinga

04:32PM EDT Sarepta Therapeutics Investigational Gene GlobeNewswire Inc

08:16AM EDT The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq Benzinga

Mar 16, 2021

07:57AM EDT Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors Benzinga

Mar 15, 2021

08:30AM EDT -- Ten abstracts, including four podium presentations, reflect Sareptas ongoing commitment to advancing genetic medicine for rare neuromuscular disease and facilitating greater understanding of these devastating conditions -- GlobeNewswire Inc

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 2, 2021

06:54PM EST ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air Benzinga

11:13AM EST Sarepta Therapeutics shares were trading lower after the company reported worse-than-expected Q4 EPS and sales results. Benzinga

07:10AM EST SVB Leerink Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $126 Benzinga

Mar 1, 2021

04:35PM EST Sarepta Therapeutics Q4 Loss/share $2.40 Vs. Loss $3.16 Year Ago RTTNews

04:28PM EST Recap: Sarepta Therapeutics Q4 Earnings Benzinga

04:21PM EST Sarepta Therapeutics Q4 EPS $(1.84) Misses $(1.77) Estimate, Sales $145.14M Miss $146.29M Estimate Benzinga

04:05PM EST Net product sales for the fourth quarter and full-year 2020 of $122.6 million and $455.9 million, respectively, were pre-announced in January 2021 at the J.P. Morgan Healthcare Conference GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

07:13PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

11:53AM EST Mizuho Maintains Buy on Sarepta Therapeutics, Raises Price Target to $160 Benzinga

10:16AM EST Earnings Preview: Sarepta Therapeutics Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

04:30PM EST Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at two upcoming virtual investor conferences: GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

Feb 22, 2021

08:30AM EST Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 GlobeNewswire Inc

08:15AM EST Benzinga Pro's Top 5 Stocks To Watch For Monday, Feb. 22, 2021: NVDA, CCIV, TSLA, LESL, SRPT Benzinga

Feb 4, 2021

08:12PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

04:30PM EST -- The four winning lesson plans are now available on sharemylesson.com -- Lesson plans showcase creative ways to build awareness of rare disease and to build diversity and inclusion in the classroom GlobeNewswire Inc

Feb 1, 2021

05:16PM EST Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm PR Newswire

Jan 31, 2021

05:22AM EST Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates Benzinga

Jan 29, 2021

08:30PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jan 13, 2021

08:46AM EST Sarepta,Genevant Enter Research Collaboration For Lipid Nanoparticle-Based Gene Editing Therapeutics RTTNews

08:36AM EST Sarepta Therapeutics, Genevant Sciences Announce Research Collaboration For Lipid Nanoparticle-Based Gene Editing Therapeutics Benzinga

08:30AM EST -- Alliance will assess the use of Sareptas proprietary gene editing technology and Genevants proprietary LNP delivery platform for multiple neuromuscular targets -- GlobeNewswire Inc

Jan 12, 2021

01:31PM EST Investors can contact the law firm at no cost to learn more about recovering their losses GlobeNewswire Inc

10:03AM EST Benzinga's Top Upgrades, Downgrades For January 12, 2021 Benzinga

08:10AM EST Citigroup Downgrades Sarepta Therapeutics to Neutral, Announces $108 Price Target Benzinga

06:00AM EST National law firm Barr Law Group is investigating the actions of the officers and board of directors of Sarepta Therapeutics, Inc., Pluralsight, Inc., RealPage, Inc., and Principal Real Estate Income Fund. If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966. GlobeNewswire Inc

Jan 11, 2021

12:19PM EST UBS Downgrades Sarepta Therapeutics to Neutral Benzinga

Jan 9, 2021

01:15PM EST Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Firm - SRPT PR Newswire

01:02PM EST The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off Benzinga

Jan 8, 2021

06:48PM EST SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta PR Newswire

02:51PM EST Mid-Afternoon Market Update: Gold Dips 3.5%; Merus Shares Surge Benzinga

12:27PM EST Mid-Day Market Update: Dow Falls 50 Points; Chimerix Shares Spike Higher Benzinga

10:20AM EST Mid-Morning Market Update: Markets Mostly Higher; US Economy Loses 140,000 Jobs In December Benzinga

10:16AM EST ROCE Insights For Sarepta Therapeutics Benzinga

10:06AM EST Stock Alert: Sarepta Therapeutics Slips On Disappointing RTTNews

10:04AM EST Benzinga's Top Upgrades, Downgrades For January 8, 2021 Benzinga

09:18AM EST Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $73 Benzinga

08:38AM EST JP Morgan Downgrades Sarepta Therapeutics to Underweight, Announces $96 Price Target Benzinga

08:35AM EST Morgan Stanley Downgrades Sarepta Therapeutics to Equal-Weight, Lowers Price Target to $95 Benzinga

08:31AM EST Raymond James Downgrades Sarepta Therapeutics to Market Perform Benzinga

08:30AM EST Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 10:00 a.m. E.T. /7:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:20 a.m. E.T. /7:20 a.m. P.T. GlobeNewswire Inc

08:14AM EST 10 Biggest Price Target Changes For Friday Benzinga

07:34AM EST Sarepta Therapeutics Announces Results for Part 1 of Study 102 Benzinga

07:33AM EST Sarepta Therapeutics Announces Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, Met The Primary Biological Endpoint Of Micro-dystrophin Protein Expression At 12 Weeks; Did Not Achieve Statistical Significance On The Primary Functional Endpoint Benzinga

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

06:52AM EST Needham Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $166 Benzinga

04:58AM EST SVB Leerink Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $125 Benzinga

Jan 7, 2021

04:06PM EST Sarepta Therapeutics Announces Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, Met The Primary Biological Endpoint Of Micro-dystrophin Protein Expression At 12 Weeks Benzinga

04:05PM EST -- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- GlobeNewswire Inc

Dec 31, 2020

06:30PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Dec 23, 2020

08:31AM EST The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut Benzinga

Dec 22, 2020

07:45AM EST The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

08:42AM EST Sarepta Therapeutics Announces New CFO, New Chief Scientific Officer Benzinga

08:30AM EST -- Ian Estepan named chief financial officer-- Dallan Murray named chief commercial officer-- Louise Rodino-Klapac, Ph.D., named chief scientific officer-- Ty Howton, general counsel, to retire from Sarepta-- Ryan Brown named interim general counsel GlobeNewswire Inc

08:13AM EST Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $156 Benzinga

Dec 7, 2020

08:56AM EST Sarepta Therapeutics Announces Clinical Results From MOMENTUM Phase 2 Clinical Trial Of SRP-5051 In Patients With Duchenne Muscular Dystrophy Amenable To Skipping Exon 51 Benzinga

08:55AM EST -- Results from the multiple-ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation-- GlobeNewswire Inc

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 4, 2020

04:05PM EST Sarepta Therapeutics to Share Clinical Update for SRP-5051, its GlobeNewswire Inc

Nov 30, 2020

06:05PM EST Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Nov 25, 2020

08:30AM EST Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T. GlobeNewswire Inc

Nov 20, 2020

08:30AM EST -- Sarepta is honored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- GlobeNewswire Inc

Nov 11, 2020

10:54AM EST Berenberg Initiates Coverage On Sarepta Therapeutics with Hold Rating, Announces Price Target of $140 Benzinga

Nov 6, 2020

05:04PM EST Biogen's Aducanumab Fails To Win FDA Panel Backing Benzinga

12:38PM EST Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $162 Benzinga

05:16AM EST SVB Leerink Maintains Outperform on Sarepta Therapeutics, Lowers Price Target to $197 Benzinga

Nov 5, 2020

05:15PM EST Sarepta Therapeutics Q3 EPS $(1.42) Beats $(1.71) Estimate, Sales $143.92M Beat $137.43M Estimate Benzinga

05:09PM EST Sarepta Therapeutics Q3 Loss/Shr $2.50 Vs Loss $1.70 Prior Year RTTNews

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

04:30PM EST Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020 at 3:30 p.m. E.T. GlobeNewswire Inc

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 30, 2020

07:16PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Oct 28, 2020

12:38PM EDT Benzinga's Top Upgrades, Downgrades For October 28, 2020 Benzinga

08:57AM EDT UBS Initiates Coverage On Sarepta Therapeutics with Buy Rating, Announces Price Target of $212 Benzinga

Oct 22, 2020

07:36AM EDT Sarepta Reports Group Of Life Science Investors, Including Perceptive, Bain, RA Capital, Partner With Co. For $107M Series A Financing To Create AavantiBio Benzinga

07:30AM EDT Gene Therapy Company AavantiBio Launches with $107 Million Series GlobeNewswire Inc

Oct 11, 2020

06:35PM EDT IPO Outlook: Solar Power Company Array Technologies, Chinese Retailer Miniso Lead Possible 9 IPO Week Benzinga

Sep 30, 2020

06:15PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 28, 2020

08:57AM EDT Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment With SRP-9001 Investigational Micro-Dystrophin Gene Therapy For Duchenne Muscular Dystrophy Benzinga

08:56AM EDT Sarepta Therapauetics Investigational Gene Therapy SRP-9003 For Treatment Of Limb-Girdle Musclar Dystrophy Type 2E Shows Sustained Functional Improvements 18-Months After Administration Benzinga

08:55AM EDT --Resultsdemonstratecontinued safety and tolerability of SRP-9001 in fourparticipants with Duchenne -- GlobeNewswire Inc

08:55AM EDT -- Continued functional improvements wereobserved at 18 months in the low-dose cohort -- GlobeNewswire Inc

Sep 22, 2020

02:12PM EDT Sarepta Therapeutics Option Alert: Nov 20 $170 Calls Sweep (6) near the Ask: 135 @ $5.4 vs 424 OI; Earnings 11/5 After Close [est] Ref=$145. Benzinga

Sep 15, 2020

11:25AM EDT Citigroup Maintains Buy on Sarepta Therapeutics, Raises Price Target to $190 Benzinga

11:17AM EDT Sarepta Shares Quiet Following Headline On Co.'s Exondys Competitor, Pfizer, Its Duchenne Muscular Dystrophy Trial Could Start In Next Several Weeks Benzinga

11:16AM EDT Pfizer Says Dosed Additional Nine Boys With Duchenne Muscular Dystrophy Gene Therapy, No Serious Adverse Events Observed With Modified Regimen Benzinga

08:30AM EDT Sarepta Therapeutics Announces Recipients of Route 79, The GlobeNewswire Inc

Sep 14, 2020

08:42AM EDT Sarepta Therapeutics To Present New Data From Its Most Advanced Gene Therapy Programs RTTNews

08:30AM EDT --Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time -- GlobeNewswire Inc

Sep 9, 2020

05:26PM EDT Saerepta Therapeutics Provides Program For SRP-9001, Its Investigational Gene Therapy For Treatment Of Duchenne Muscular Dystrophy Benzinga

05:19PM EDT Sarepta Therapeutics Provides Program Update for SRP-9001, its GlobeNewswire Inc

Sep 3, 2020

04:30PM EDT Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in fireside chats at three upcoming virtual investor conferences: GlobeNewswire Inc

Aug 31, 2020

06:30PM EDT Sarepta Therapeutics Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

08:50AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:22AM EDT HC Wainwright & Co. Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $221 Benzinga

Aug 25, 2020

09:35AM EDT Benzinga's Top Upgrades, Downgrades For August 25, 2020 Benzinga

08:46AM EDT Sarepta Therapeutics Announces FDA Acceptance Of Casimersen New Drug Application For Patients With Duchenne Muscular Dystrophy Amenable To Skipping Exon 45 Benzinga

08:45AM EDT Sarepta Therapeutics Announces FDA Acceptance of Casimersen GlobeNewswire Inc

06:33AM EDT Raymond James Initiates Coverage On Sarepta Therapeutics with Outperform Rating, Announces Price Target of $200 Benzinga

Aug 21, 2020

07:16AM EDT B of A Securities Maintains Buy on Sarepta Therapeutics, Lowers Price Target to $189 Benzinga

Aug 20, 2020

09:51AM EDT Benzinga's Top Upgrades, Downgrades For August 20, 2020 Benzinga

08:52AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

06:13AM EDT A Peek Into The Markets: US Stock Futures Drop Ahead Of Earnings, Jobless Claims Data Benzinga

04:46AM EDT Credit Suisse Downgrades Sarepta Therapeutics to Neutral, Lowers Price Target to $167 Benzinga

Aug 11, 2020

08:54AM EDT Sarepta Therapeutics Inc. (SRPT) and the University of Florida have collaborated to accelerate the discovery and development of therapies for rare genetic diseases, the company said in a statement. RTTNews

08:42AM EDT Sarepta Therapeutics Reports Collaboration With University Of Florida To Accelerate Discovery, Development Of Therapies For Rare Genetic Diseases Benzinga

08:39AM EDT Sarepta, University Of Florida Collaborate To Enable Research For Novel Genetic Medicines RTTNews

08:30AM EDT Sarepta Therapeutics and University of Florida Announce GlobeNewswire Inc

Aug 10, 2020

09:29AM EDT Morgan Stanley Maintains Overweight on Sarepta Therapeutics, Raises Price Target to $182 Benzinga

Aug 6, 2020

11:13AM EDT Cramer Weighs In On Lumentum, American Airlines And More Benzinga

Aug 5, 2020

04:40PM EDT Sarepta Therapeutics Q2 EPS $(1.51) Beats $(1.72) Estimate, Sales $111.30M Miss $118.78M Estimate Benzinga

04:05PM EDT Net product sales of $111.3 million, an 18% increase over same quarter of prior year GlobeNewswire Inc